Johnson & Johnson has announced that Janssen Pharmaceuticals, a member of the Johnson & Johnson family of companies, has entered into a research study in collaboration with Apple.
It will investigate whether a new heart health program using an app from Johnson & Johnson in combination with Apple Watch’s irregular rhythm notifications and ECG app can accelerate the diagnosis and improve health outcomes of the 33 million people worldwide living with atrial fibrillation (AFib), a condition that can lead to stroke and other potentially devastating complications. In the U.S. alone, AFib is responsible for approximately 130,000 deaths and 750,000 hospitalizations every year.
The study aims to analyze the impact of Apple Watch on the early detection and diagnosis of AFib, and the potential to improve outcomes including the prevention of stroke. A multi-year research program will be launched later in 2019. This large-scale program will occur in the U.S. only, and will be designed as a pragmatic randomized controlled research study for individuals age 65 years or older.
The study’s goals include:
° Measuring the outcomes of a heart health engagement program with irregular rhythm notifications on Apple Watch.
° Assessing the impact of a medication adherence program using an app from Johnson & Johnson.